I've been eyeballing Cynosure (NASDAQ:CYNO) as a potential short for some time. The company was one of a group of energy-based medtech stocks to go public in the middle of the last decade, along with Cutera (NASDAQ:CUTR), Syneron (NASDAQ:ELOS), Candela (later merged with Syneron), and Solta Medical (bought out below $3 by Valeant Pharmaceuticals (NYSE:VRX)). The space as a whole had been a disappointment; while the recession certainly impacted the economically-sensitive aesthetics space as a whole, there were also a series of execution problems among the companies, and a concern that demand simply wasn't enough to support these publicly-traded companies, smaller private rivals, and competitive and/or similar products from larger public peers.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|